Abstract | PURPOSE: PATIENTS AND METHODS: It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. RESULTS: Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. CONCLUSION:
Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.
|
Authors | Clovis O da Fonseca, Marcela Simão, Igor R Lins, Regina O Caetano, Débora Futuro, Thereza Quirico-Santos |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 137
Issue 2
Pg. 287-93
(Feb 2011)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 20401670
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Monoterpenes
- perillyl alcohol
|
Topics |
- Administration, Intranasal
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Brain Neoplasms
(drug therapy, mortality, pathology)
- Drug Administration Schedule
- Female
- Glioblastoma
(drug therapy, mortality, pathology)
- Humans
- Kaplan-Meier Estimate
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Monoterpenes
(administration & dosage, therapeutic use)
- Neoplasm Recurrence, Local
(drug therapy, mortality, pathology)
- Patient Selection
|